Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xeris Pharmaceuticals Inc 1375 West Fulton Street Suite 1300 Chicago IL 60607 USA

www.xerispharma.com Employees: 435 P: 844-445-5704

Sector:

Medical

Description:

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.

Key Statistics

Overview:

Market Capitalization, $K 1,000,100
Enterprise Value, $K 1,109,400
Shares Outstanding, K 172,431
Float, K 161,275
% Float 93.53%
Short Interest, K 16,223
Short Float 9.41%
Days to Cover 6.77
Short Volume Ratio 0.32
% of Insider Shareholders 6.47%
% of Institutional Shareholders 42.75%

Financials:

Annual Sales, $ 291,850 K
Annual Net Income, $ 550 K
Last Quarter Sales, $ 85,810 K
Last Quarter Net Income, $ 11,080 K
EBIT, $ 35,730 K
EBITDA, $ 51,800 K

Growth:

1-Year Return 18.90%
3-Year Return 219.58%
5-Year Return 42.79%
5-Year Revenue Growth 1,327.84%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.06 on 03/02/26
Next Earnings Date 05/14/26
Earnings Per Share ttm -0.01
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 300.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

XERS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 47.66
Price/Earnings to Growth N/A
Return-on-Equity % -5.33%
Return-on-Assets % 0.16%
Profit Margin % 0.19%
Debt/Equity 16.09
Price/Sales 3.31
Price/Cash Flow 55.91
Price/Book 67.88
Book Value/Share 0.08
Interest Coverage -1.02
60-Month Beta 0.61
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.